Beam would be the popular one. They were one of the first to invent the base and prime editing (as contrasted with traditional CRSP Case-9 editing the likes of which is used by CRSP Therapeutics). But Intelia now has a base editor?
For long-term investors, who want to bet on the utility of BASE editing, what would your play be? I already have 2% of my account in CRSP. Would like to add 2% into a base editing genomics company. I'm thinking Beam right now.
Here's a bit of background: https://www.statnews.com/2019/11/06/questions-david-liu-crispr-prime-editing-answers/
Submitted June 06, 2021 at 08:40AM by see-the-whole-board https://ift.tt/3vWyWW5
